Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00892827|
Recruitment Status : Unknown
Verified September 2010 by Wolfson Medical Center.
Recruitment status was: Recruiting
First Posted : May 5, 2009
Last Update Posted : September 14, 2010
|Condition or disease||Intervention/treatment||Phase|
|Advanced Refractory Chronic Lymphocytic Leukemia||Drug: Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)||Phase 2|
Indolent B cell Non-Hodgkin's lymphoma patients show good responses to Rituximab, administered either alone or preferably with standard chemotherapy. The response to Rituximab of patients with CLL is inferior in comparison to other indolent B cell malignancies. The therapeutic approach of combining treatments with Rituximab and fresh frozen plasma (FFP) used by us first in one case and following the impressive response - in additional 2 patients, was undertaken on the basis of two observations.
We assumed, that the addition of FFP to Rituximab treatment would increase and/or restore the efficacy of Rituximab in advanced CLL patients that are resistant to therapy by correcting their abnormal complement system thus allowing improved complement activation and increase anti-leukemic activity.
The major aims of the study are: (1) To establish the efficacy of the combination of FFP and RTX as determined by response rate. (2) To elucidate the effector mechanism responsible for the efficacy of the FFP-Rituximab combination. The secondary aims of the study are (1) To establish the response duration of the combination of FFP and RTX as determined by time to progression. and time to re treatment (2) To determine the safety of the combined treatment.
The study is designed as a single-arm, phase II study evaluating the efficacy and safety of combined treatment with FFP and RTX in advanced refractory chronic lymphocytic leukemia, along with an analysis of the complement system associated parameters.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Efficacy and Safety of Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia. Single-arm Phase II Study. Analysis of Complement Activation Pathways.|
|Study Start Date :||April 2009|
|Estimated Primary Completion Date :||July 2009|
|Estimated Study Completion Date :||December 2010|
Experimental: Single Arm Study
Drug: Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)
Rituximab (375 mg/m2) with FFP will be given every two weeks
- To establish the efficacy of the combination of FFP and RTX as determined by response rate. Complete/Partial Response includes parameters: Physical Exam,Symptoms,Lymphocytes, Neutrophils, Platelets,Hb (g/dL),Bone marrow lymph [ Time Frame: 3 months ]
- Time to disease progression [ Time Frame: 6-12 months ]
- Time to re-treatment [ Time Frame: 6-12 months ]
- Safety of the combination treatment of FFP and RTX [ Time Frame: 6-12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00892827
|Holon, Israel, 58100|
|Contact: Abraham Klepfish, MD 972-35028778 firstname.lastname@example.org|
|Sub-Investigator: Goldstein Daniela, MD|
|Sub-Investigator: Gil Lugassy, Prof.|
|Sub-Investigator: Ami Schattner, Prof.|